Navigation Links
Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Date:5/13/2008

CALGARY, May 14 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical Trial Application (CTA) to begin a Phase II clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers. The principal investigator is Dr. Kevin Harrington of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.

"Interim data recently presented from our U.K. Phase I dose escalation trial of REOLYSIN(R) in combination with paclitaxel and carboplatin indicated strong and durable responses in patients with advanced head and neck cancers," said Dr. Brad Thompson, President and CEO of Oncolytics. "We believe it is important to further explore these findings by conducting a Phase II trial in this specific patient population."

This trial is a 14 patient, single arm, open-label, dose-targeted, non-randomized, multi-centre trial of REOLYSIN(R) given intravenously in combination with a standard dosage of paclitaxel and carboplatin. Patients with a variety of advanced cancers, including head and neck cancers, will continue to be treated in the ongoing U.K. combination paclitaxel and carboplatin trial.

Eligible patients include those with advanced or metastatic head and neck cancer that are refractory to standard therapy or for which no curative standard therapy exists. The primary objective of the Phase II trial is to measure tumour responses and duration of response, and to describe any evidence of antitumour activity. The secondary objective is to determine the safety and tolerability of REOLYSIN(R) when administered in combination with paclitaxel and carboplatin to patients with advanced or metastatic head and neck cancer.

About Oncolytics Biotech Inc.

Oncolytic
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... Drug companies increasingly ... BCC Research reveals in its new report that the U.S. will generate ... category and generates the most market demand. , BCC Research examines plant-derived ...
(Date:9/2/2015)... , Sept. 2, 2015 Aytu BioScience, ... developing treatments for urological and related conditions, announced today ... planned private placement convertible note financing, raising a total ... tranches totaling $3.175 million. Josh ... from this private placement are intended to be used ...
(Date:9/2/2015)... , September 2, 2015 BiondVax Pharmaceuticals ... the National Institute of Allergy and Infectious Diseases (NIAID), part ... Department of Health and Human Services (HHS), to launch a ... the United States in the 2015-16 timeframe. The ... candidate, Multimeric-001 (M-001), as a primer vaccine, which would be ...
(Date:9/2/2015)... ... September 02, 2015 , ... Whitehouse Laboratories is excited to ... Ed Resources upcoming educational seminar and training session on Extractable & Leachable testing. ... will provide Updates & Case Studies on the Latest Compliance Implications of USP ...
Breaking Biology Technology:Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3
... Top 25 Global Pharmaceutical Companies Select Drug ... Visualization, MOUNTAIN VIEW, Calif., April 2, 2008 ... provider of software,strategic consulting, and regulatory services for ... 25 global pharmaceutical,companies have become customers for its ...
... 1, 2008 MiMedx Group, Inc.,(OTC Bulletin Board: ... AYXC), today reported that the contemplated reverse stock ... related name change, to,MiMedx Group, Inc., was approved ... a result of the reverse split and redomestication, ...
... Installation and Major Data Migration in ... United States and Abroad, CHICAGO, April 1, ... signed an agreement with the Cleveland,Clinic, a not-for-profit ... deploy the syngo(R) Dynamics cardiology image,management and reporting ...
Cached Biology Technology:Pharsight Signs Two New DMX(R) License Customers 2Pharsight Signs Two New DMX(R) License Customers 3MiMedx Group Announces Post-split Name Change 2MiMedx Group Announces Post-split Name Change 3Siemens Signs Multi-Year Agreement With Cleveland Clinic to Deploy Enterprise-Wide Cardiology PACS 2
(Date:8/24/2015)... August 24, 2015 The consulting company ... largest biometrics manufacturer DERMALOG and its customized solutions and products ... Biometrics Company of the Year Award". DERMALOG is particularly successful ... .   -Cross reference: Picture is available at ... On Thursday evening, in South Africa,s ...
(Date:8/20/2015)... , Aug. 20, 2015   Sensory, Inc ... improving the user experience and security of consumer ... today announced that its TrulySecure™ is ... software to be FIDO Certified™. The ... compliance with the FIDO UAF (Universal Authentication Framework) ...
(Date:8/18/2015)... PRINCETON, N.J. , Aug. 18, 2015 ... be a key contributor to the Submission ... hosted by IRISS, a non-profit forum. Dedicated to ... IRISS provides a neutral platform for industry, ... to share information and work towards a ...
Breaking Biology News(10 mins):Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... 9, 2012 New research reveals that insulin applied ... elastic fibers in cultures of human aortic smooth muscle ... molecular and cellular mechanisms of diabetic vascular disease. ... the American Journal of Pathology . "Our ...
... the University of Iowa have worked out the exact function ... and is involved in several muscular dystrophies. The findings, which ... could be used to develop rapid, large-scale testing of potential ... critical sugar chain onto an important membrane protein called dystroglycan. ...
... Hackers invading databases is just the tip of the iceberg ... Internet activity focus to social networks and today a number ... Hezbollah, Hamas and other armed groups that have been included ... been shown in a new study conducted by Prof. Gabriel ...
Cached Biology News:Insulin therapy may help repair atherosclerotic lesions in diabetic patients 2Study reveals enzyme function, could help find muscular dystrophy therapies 2Study reveals enzyme function, could help find muscular dystrophy therapies 3A 'friend' request from al-Qaida 2
Sf21 cells derived from Spodoptera frugiperda ovarian cells are recommended for high-level production of recombinant proteins. Higher expression levels of some proteins are seen due to the larger ce...
... offers the most comprehensive, cost-effective solution ... have incorporated unprecedented quality into both ... includes proven detection chemistries and antibodies ... TechMate protocol. It also includes our ...
Functionally tested for consistent G-banding of chromosomes....
... Cell Medium is optimized for serum-free growth ... In this protein-free medium, Sf9 cultures routinely ... cells/ml with viabilities above 95%. This medium ... color from X-gluc staining of pBACgus recombinants ...
Biology Products: